Association of COX-2 rs20417 with aspirin resistance

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 1, 2013, Pages 95-99

  Sharma, Vandana ^a,b   Kaul, Subhash ^c   Al Hazzani, Amal ^d   Alshatwi, Ali A ^d   Jyothy, A ^a   Munshi, Anjana ^a  

^a OSMANIA UNIVERSITY   (India)

^b Dr NTR University of Health Sciences   (India)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Aspirin resistance; Cyclooxygenase 2 gene (COX 2); Genetics; Pharmacogenetics; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CYCLOOXYGENASE 2;

ADULT; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DNA ISOLATION; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANKIN SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ASPIRIN; BRAIN ISCHEMIA; CYCLOOXYGENASE 2; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; STROKE;

EID: 84871734951     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0777-8     Document Type: Article

References (25)

1. Antithromobotic Trialists Collaboration (2002) Collaboration meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71-86
2. Nutiu R, Bolcu C, Modra D, Albulescu M, Lagher R, Heiman C (2003) Practice in organic chemistry, vol 2 (in Romania). Eurostampa Publishing House, Timisoara, p 37
3. Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest Physicians (2008) Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6):199S-233S
4. Wang D, Mann JR, Du Bois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445-1461
5. Patrono C, Coller B, Fitz-Gerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3):234S-264S
6. Schrör K (2006) Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches. Hamostaseologie 26(2):104-105
7. Catella-Lawson F, Reilly MP, Kapoor SC, Andrew JC, Demarco S, Barbara R, Tournier B et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809-1817
8. Cohen HW, Crandall JP, Hailpern SM, Billett HH (2008) Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complicat 22(3):224-228
9. Mansour K, Taher AT, Musallan KM, Alams S (2009) Aspirin resistance. Adv Hematol. doi: 10.1155/2009/937352
10. Goodman T, Sharma P, Ferro A (2007) The genetics of aspirin resistance. Int J Clin Pract 61:826-834
11. Tourmousoglou CE, Rokkas CK (2008) Clopidogrel and aspirin in cardiovascular medicine responders or not-current best available evidence. Cardiovasc Hematol Agents Med Chem 6(4):312-322
12. Papafili A, Hill MR, Brull DJ, Mcanulty RJ, Marshall RP, Humphries SE et al (2008) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631-1636
13. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST (Trial of Org 10172 in Acute Stroke Treatment). Stroke 24:35-41
14. Munshi A, Sultana S, Kaul S, Pulla Reddy B, Alladi S et al (2008) Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischemic stroke in a South Indian population. J Neurol Sci 272:132-135
15. Kupari M, Hautanen A, Lankinen I, Koskinen P, Virolainen J, Nikkila H et al (1998) Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass and function. Circulation 97:569-575
16. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
17. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D et al (1997) Variable platelet response to low dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007
18. Hankey GJ, Eikebboon JN (2006) Aspirin resistance. Lancet 367:606-617
19. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwinder SK, Narain VS et al (2005) Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J 57:658-661
20. Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66(2):222-232
21. Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT et al (2008) Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2)G -765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196(2):926-930
22. Colaizzo D, Fofi L, Tiscia G (2006) The COX-2G/C -765 polymorphism may modulating the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 17:93-96
23. Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RY (2006) Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost 4(8):1718-1722
24. Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, Ilveskoski E, Karhunen PJ et al (2008) COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm 2008:289453
25. Maguire J, Thakkkinskian A, Levi C, Lineze L, Bisset L, Sturm J et al (2010) Impact of COX-2 rs5275 and rs20417 and GP IIIa rs5918 polymorphism on 90 day ischemic stroke functional outcome; A novel finding. J Stroke Cerebrovasc Dis. doi: 10.1016/i.jstrokecerebrovasdis.2009.10.011